LKT Labs

Biochemicals for Life Science Research

Dabrafenib

Dabrafenib

Product ID D0004
Cas No. 1195765-45-7
Purity ≥98%
Product Unit SizeCostQuantityStock
5 mg $75.10 In stock
25 mg $202.90 In stock
100 mg $721.20 In stock
Bulk Quote

Quicklinks

Description

Dabrafenib is a reversible kinase inhibitor with anticancer chemotherapeutic activity. This compound is selective primarily for mutant (V600E) B-Raf, but has also inhibited tumor growth in cells expressing other B-Raf mutants (V600K, V600D) and WT B-Raf. Dabrafenib is partially active against c-Raf as well. Dabrafenib is an ATP-competitive inhibitor that has been approved for clinical use in the treatment of unresectable or metastatic melanomas; it is also being examined for treatment of brain metastases and other cancers. This compound has a very high oral bioavailability.

Product Info

Cas No.

1195765-45-7
Purity

≥98%
Formula

C23H20F3N5O2S2
Formula Wt.

519.56
Chemical Name

N-[3-[5-(2-aminopyrimidin-4-yl)-2-tert-butyl-1, 3-thiazol-4-yl]-2-fluorophenyl]-2,6-difluorobenzenesulfonamide
IUPAC Name

N-[3-[5-(2-aminopyrimidin-4-yl)-2-tert-butyl-1, 3-thiazol-4-yl]-2-fluorophenyl]-2,6-difluorobenzenesulfonamide
Synonym

GSK2118436A
Solubility

soluble in DSMO
Appearance

White Crystal Powder

Shipping and Storage

Store Temp

-20°C
Ship Temp

Ambient

Downloads

MSDS

D0004 MSDS PDF
Info Sheet

D0004 Info Sheet PDF
Brochures

Ras-Raf-MEK-ERK Pathway Booklet

References

Ballantyne AD, Garnock-Jones KP. Dabrafenib: First Global Approval. Drugs. 2013 Jul 24. [Epub ahead of print] PMID: 23881668.

Huang T, Karsy M, Zhuge J, et al. B-Raf and the inhibitors: from bench to bedside. J Hematol Oncol. 2013 Apr 25;6:30. PMID: 23617957.

Klinac D, Gray ES, Millward M, et al. Advances in personalized targeted treatment of metastatic melanoma and non-invasive tumor monitoring. Front Oncol. 2013;3:54. PMID: 23515890.

Hauschild A, Grob JJ, Demidov LV, et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet. 2012 Jul 28;380(9839):358-65. PMID: 22735384.

Custom Order

  • Size of single unit expressed as number (e.g. '500' in the case of 500 mg)
  • Total quantity of unit size desired (e.g. '10' in the case of 10 x 500 mg). If only one unit is desired, you may leave this blank.
  • This field is for validation purposes and should be left unchanged.

Related Products

  • T6932

    Triflumizole

    Imidazole; PPARγ agonist, RORγ inverse agonis...

    ≥95%
  • P0932

    PCI-32765

    BTK and IL-2-inducible kinase inhibitor.  
    ≥99%
  • N0212

    Nedaplatin

    Pt-based DNA cross-linker.

    ≥98%
  • C4000

    CK-636

    Arp2/3 inhibitor.

    ≥98%
  • V3455

    Vinpocetine

    Targets nuclear factor kappa B activation.

    ≥98%
  • I538583

    Inosine

    Adenosine analog

    ≥98%
  • C3446

    Cilnidipine

    Dihydropyridine; L-type and N-type Ca2+ channel...

    ≥98%
  • N8604

    NVP-BGT226

    PI3K and mTOR inhibitor.

    ≥98%
  • G1200

    GDC-0068

    Akt inhibitor.

    ≥98%
  • T3357

    Tioconazole

    Imidazole; 14-α demethylase inhibitor.

    ≥98%
  • N3228

    Nifedipine

    Dihydropyridine; L-type Ca2+ channel blocker.

    ≥98%
  • C2847

    Chlormadinone Acetate

    Synthetic steroid hormone; AR and ER antagonist. ...
    ≥96%
  • E7668

    Etretinate

    Aromatic retinoid; RAR, RXR agonist.

    ≥98%
  • A985136

    AZD5991

    Mcl-1 inhibitor

    ≥99%
  • P6854

    Progesterone

    Endogenous steroid hormone involved in reproduc...

    ≥98%
  • P0219

    Paeonol

    Found in Paeonia, Arisaema, Dioscorea; MAO-A/B ...

    ≥98%
  • M1669

    6-Mercaptopurine Monohydrate

    Thiopurine antimetabolite; PRPP amidotransferas...

    ≥98%
  • N8561

    NVP-AEW541

    IGF-1R inhibitor.

    ≥98%
  • P7718

    Pterostilbene

    Stilbene, resveratrol analog.

    ≥98%
  • H9815

    25-Hydroxyvitamin D3

    Vitamin D, calcitriol prodrug; VDR agonist.

    ≥98%